Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lonza Group and Kyowa Hakko Kogyo have signed an agreement, whereby Lonza will license to Kyowa Hakko and its US subsidiary BioWa its glutamine synthetase Gene Expression System.
Subscribe to our email newsletter
Prior to this agreement BioWa and Lonza entered into a strategic research collaboration agreement combining Kyowa Hakko’s Potelligent technology with Lonza’s glutamine synthetase (GS) Gene Expression System.
This worldwide, non-exclusive umbrella research and license agreement enables Kyowa Hakko Group to use Lonza’s proprietary GS-System and the Potelligent technology as a platform for the production of antibodies and recombinant proteins being developed by Kyowa Hakko Group.
Nobuo Hanai, managing officer, head of pharmaceutical R&D Division of Kyowa Hakko, said: “We are excited about the combination of our Potelligent technology with Lonza’s GS Gene Expression System which has potential to strengthen Kyowa Hakko Group’s production system for biological drugs.”